Anti-hPD-L1-mIgG1 features a variable region equivalent to that of Atezolizumab, a therapeutic monoclonal antibody (mAb) that targets PD-L1, blocking the interaction with its receptor PD-1. Atezolizumab (formerly known as MPDL3280A) is a fully-humanized IgG1 mAb with a modified Fc region designed to limit antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [1, 2]. It contains an N298A mutation that eliminates its ability to bind to human Fcγ receptors. In contrast to nivolumab, a therapeutic mAb that targets only human PD-1, Atezolizumab targets both human and mouse PD-L1.
To enable studies in mice, InvivoGen's Anti-hPD-L1-mIgG1 contains the constant region of mouse IgG1; an isotype exhibiting low CDC and no ADCC. Anti-hPD-L1-mIgG1 was generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography with protein G.
Anti-hPD-L1-mIgG1 InvivoFit™ is specifically designed for mouse studies:
- Contains a mouse IgG1 Fc domain to prevent ADAs (anti-drug-antibodies)
- Guaranteed sterile
- Endotoxin level
- Low aggregation, < 5%
- No preservative
- Binding validated by flow cytometry using EL4 cells expressing membrane-bound mouse PD-L1
The terms “Atezolizumab” and “MPDL3280A” are only used as references. Anti-hPD-L1-mIgG1 is not a pharmaceutical biosimilar of Atezolizumab. It has not been developed nor approved by Atezolizumab owner(s), and is not intended for any therapeutic or diagnostic use in humans or animals.
References:
- Spigel D. et al., 2013. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [ASCO abstract 8008]. J Clin Oncol. 31(15)(suppl).
- Herbst RS. et al., 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515(7528):563-7.
